EGFR and head and neck cancer: Rakuten Medical, Inc. is commercializing Cetuximab Sarotalocan, also known as ASP-1929 (RM-1929) or cetuximab-IRDye 700DX conjugate, which is an anti-[EGFR (epidermal growth factor receptor), avian erythroblastic leukemia viral oncogene homolog], chimeric monoclonal antibody (mAb) conjugated covalently to IRDye 700DX (cet-IR700) near-infrared photosensitizing dye [73,74], that received accelerated approval from the FDA in January 2018 for the treatment of recurrent head and neck cancer (rHNC).